Richter says cariprazine effective in high doses

BUDAPEST, Aug 30 (BestGrowthStock) – Hungarian group Richter Gedeon
(GDRB.BU: ) said tests of cariprazine, a new agent for the
treatment of bipolar depression, showed it was effective in a
high dose version.

“Although the overall difference observed between
the drug-treated and placebo-treated groups was not
statistically significant, over the course of the trial there
was evidence of a clinically relevant treatment effect
in the high-dose arm of the study by comparison to placebo,”
Richter said on Monday.

“The companies are considering conducting an additional
Phase II dose-response trial examining a wider range of doses,”
it said.

Richter, developing cariprazine with U.S. partner Forest
Labs Inc (FRX.N: ), said 233 patients took part in the trial of
two active low dose or high dose treatments or placebo.

Cariprazine had shown a reduction in symptoms in previously
reported Phase II clinical trials for schizophrenia and
bipolar mania and is undergoing Phase III trials for this.
(Reporting by Krisztina Than; Editing by Dan Lalor)

Richter says cariprazine effective in high doses